UTHR

NEUTRALEarnings

United Therapeutics Corporation

2026-02-25

Price

$535.10

+13.03%

Score12.5Priority

Signals2/8 DNA4/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume3.1xvs 20d avg

Analysis

UTHR is executing a high-conviction 'Quality Breakout' driven by a massive profitability beat and a surprise strategic checkmate against competitor MannKind. While Q4 revenue slightly missed estimates (-3%), the market is aggressively repricing the asset on a robust EPS beat ($7.70 vs $7.10) and the unveiling of the 'Tresmi' soft-mist inhaler, which reinforces its long-term moat in the PAH market. This price action is a textbook 'Institutional Absorption' event: smart money is ignoring the top-line noise to position for the $4B 2027 guidance and upcoming TETON-1 data, perfectly aligned with the current RISK_ON (EARNINGS) regime.

Fired Signals

ALPHA MALEGOLDEN CROSSQUIET ACCUMULATIONBREAKOUTSMA BOUNCEINSIDE OUTWEAK FINISH

Key Takeaways

The 'Moat' Catalyst: The new soft-mist inhaler announcement caused rival MNKD to crash ~37%, signaling a structural shift in market share dominance toward UTHR.
Volume Speaks Truth: 3.2x average volume on a revenue miss confirms that institutions are prioritizing earnings power and pipeline innovation over short-term sales variances.
Technical Leadership: With RS +12.6% vs SPY and a breakout to all-time highs, UTHR has decoupled from the broad market's macro anxiety to trade on its own idiosyncratic alpha.

← Back to 2026-02-25 View Full UTHR History →Yahoo Finance &nearr;